2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 557

Enhanced Expression of NLRP3 Inflammasome-Related Inflammation in Peripheral Blood Mononuclear Cells in Sjögren’s Syndrome

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 85

Enhanced IFN-γ STAT1 Signaling in CD4 T Cell Populations and Attenuated IL-2 STAT5 Signaling Contribute to the Pathogenesis of Rheumatoid Arthritis (RA)

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster I: The Variable World of Intercellular Signalling

9:00AM-11:00AM: Abstract Number: 209

Epidemiologic Subsets Drive a Differentiated Thoracic and Extrathoracic Presentation of Sarcoidosis: Analysis of 1082 Patients from the Sarcogeas-SEMI Registry

Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 806

Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 13

Epidemiology of Antiphospholipid Syndrome: A Population-Based Study

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 589

Erosions at the Sacroiliac Joints and Fatty Lesions at the Spine Are the Most Discriminant Lesions for Recent Onset Axial Spondyloarthritis Recognition

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 140

Estimating Prevalence and Cost of Depression Among Japanese RA Patients: A Retrospective Claims Data Base Analysis

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 733

Ethnic Variation in Systemic Sclerosis Morbidity and Mortality

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 783

European League Against Rheumatisms Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 193

Evaluation of a Diversionary Back Pain Service

Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 242

Evaluation of Bone Erosions in Rheumatoid Arthritis Patients Using Cone Beam Computed Tomography, Magnetic Resonance Imaging, and Ultrasound

Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 368

Evaluation of Efficacy and Safety of Opocalcium Colchicine, and Anti-IL1 Treatment in Childhood Colchicine-Resistant Familial Mediterranean Fever

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Autoinflammatory Disorders and Miscellaneous

9:00AM-11:00AM: Abstract Number: 323

Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated for up to 10 Years with Denosumab: Results from a Phase 3 Open-Label Extension Study

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 360

Evaluation of the Educational Needs in Argentinian Patients with Rheumatoid Arthritis Using the SpENAT Questionnaire

Patient Outcomes, Preferences, and Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 517

Evaluation of the Effectiveness of Injectable Methotrexate for the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].